Is it really myositis? A consideration of the differential diagnosis

Current Opinion in Rheumatology

Volumn 16, Issue 6, 2004, Pages 684-691

  Nirmalananthan, Niranjanan ^a,b   Holton, Janice L ^a,b   Hanna, Michael G ^a,b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

Author keywords

Diagnosis; Inflammatory myopathies; Muscular dystrophies; Myositis

Indexed keywords

CARNITINE; CREATINE KINASE MB; IMMUNOSUPPRESSIVE AGENT;

BECKER MUSCULAR DYSTROPHY; CARNITINE DEFICIENCY; CLINICAL EXAMINATION; CLINICAL FEATURE; DERMATOMYOSITIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC ERROR; DIAGNOSTIC PROCEDURE; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE COURSE; DUCHENNE MUSCULAR DYSTROPHY; ELECTROMYOGRAPHY; ELECTRON MICROSCOPY; ENDOCRINE DISEASE; FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY; GLYCOGEN STORAGE DISEASE TYPE 5; HISTOPATHOLOGY; HUMAN; IDIOPATHIC INFLAMMATORY MYOPATHY; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE TREATMENT; LABORATORY DIAGNOSIS; LIMB GIRDLE MUSCULAR DYSTROPHY; LIPIDOSIS; METABOLIC DISORDER; MITOCHONDRIAL MYOPATHY; MIYOSHI MYOPATHY; MUSCLE BIOPSY; MUSCLE DISEASE; MUSCULAR DYSTROPHY; MYOSITIS; POLYMYOSITIS; PRIORITY JOURNAL; REVIEW; SERODIAGNOSIS; TREATMENT OUTCOME;

DIAGNOSIS, DIFFERENTIAL; ENDOCRINE SYSTEM DISEASES; HUMANS; METABOLIC DISEASES; MUSCULAR DYSTROPHIES; MYOSITIS;

EID: 7044226535     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.bor.0000143441.27065.bc     Document Type: Review

References (58)

1. Engel AG, Arahata K: Mononuclear cells in myopathies: quantitation of functionally distinct subsets, recognition of antigen-specific cell-mediated cytotoxicity in some diseases, and implications for the pathogenesis of the different inflammatory myopathies. Hum Pathol 1986, 17:704-721.
2. Dalakas MC: Polymyositis, dermatomyositis and inclusion-body myositis. N Engl J Med 1991, 325:1487-1498.
3. Askanas V, Engel WK: Proposed pathogenetic cascade of inclusion-body myositis: importance of amyloid-beta, misfolded proteins, predisposing genes, and aging. Curr Opin Rheumatol 2003, 15:737-744. This is a detailed review of what is currently known of the pathogenesis of IBM.
4. Dalakas MC, Hohlfeld R: Polymyositis and dermatomyositis. Lancet 2003, 362:971-982.
5. Hilton-Jones D: Diagnosis and treatment of inflammatory muscle diseases. J Neurol Neurosurg Psychiatry 2003, 74(suppl 2):ii25-ii31.
6. Mastaglia FL, Garlepp MJ, Phillips BA, et al.: Inflammatory myopathies: clinical, diagnostic and therapeutic aspects. Muscle Nerve 2003, 27:407-425. A highly comprehensive recent review of the idiopathic inflammatory myopathies.
7. van der Meulen MF, Bronner IM, Hoogendijk JE, et al.: Polymyositis: an over-diagnosed entity. Neurology 2003, 61:316-321. A detailed clinicopathologic study of the subclassification of inflammatory myopathy by Bohan and Peter and more recent histopathologic criteria are reported.
8. Bohan A, Peter JB: Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975, 292:344-347.
9. Bohan A, Peter JB, Bowman RL, et al.: Computer-assisted analysis of 153 patients with polymyositis and dermatomyositis. Medicine (Baltimore) 1977, 56:255-286.
10. Mastaglia FL, Phillips BA: Idiopathic inflammatory myopathies: epidemiology, classification, and diagnostic criteria. Rheum Dis Clin North Am 2002, 28:723-741.
11. Gran JT, Myklebust G, Johansen S: Adult idiopathic polymyositis without elevation of creatine kinase. Case report and review of the literature. Scand J Rheumatol 1993, 22:94-98.
12. Rider LG, Miller FW: Laboratory evaluation of the inflammatory myopathies. Clin Diagn Lab Immunol 1995, 2:1-9.
13. Hengstman GJ, Ter Laak HJ, van Engelen BG, et al.: Anti-Jo-1 positive inclusion body myositis with a marked and sustained clinical improvement after oral prednisone. J Neurol Neurosurg Psychiatry 2001, 70:706.
14. Selva-O'Callaghan A, Mijares-Boeckh-Behrens T, Labrador-Horrillos M, et al.: Anti-PM-Scl antibodies in a patient with inclusion body myositis. Rheumatology (Oxford) 2003, 42:1016-1018.
15. Funauchi M, Nozaki Y, Yoo BS, et al.: A case of limb-girdle muscular dystrophy with serum anti-nuclear antibody which led to a mistaken diagnosis of polymyositis. Clin Exp Rheumatol 2002, 20:707-708.
16. Dabby R, Lange DJ, Trojaborg W, et al.: Inclusion body myositis mimicking motor neuron disease. Arch Neurol 2001, 58:1253-1256.
17. Dalakas MC: Muscle biopsy findings in inflammatory myopathies. Rheum Dis Clin North Am 2002, 28:779-798.
18. Lundberg I, Brengman JM, Engel AG: Analysis of cytokine expression in muscle in inflammatory myopathies, Duchenne dystrophy, and non-weak controls. J Neuroimmunol 1995, 63:9-16.
19. Arahata K, Ishihara T, Fukunaga H, et al.: Inflammatory response in facioscapulohumeral muscular dystrophy (FSHD): immunocytochemical and genetic analyses. Muscle Nerve 1995, 2:356-366.
20. Fanin M, Angelini C: Muscle pathology in dysferlin deficiency. Neuropathol Appl Neurobiol 2002, 28:461-470.
21. Pegoraro E, Mancias P, Swerdlow SH, et al.: Congenital muscular dystrophy with primary laminin alpha2 (merosin) deficiency presenting as inflammatory myopathy. Ann Neurol 1996, 40:782-791.
22. Matsubara S, Hirai S, Sawa Y: Pulsed intravenous methylprednisolone therapy for inflammatory myopathies: evaluation of the effect by comparing two consecutive biopsies from the same muscle. J Neuroimmunol 1997, 76:75-80.
23. van der Pas J, Hengstman GJ, Ter Laak HJ, et al.: Diagnostic value of MHC class I staining in idiopathic inflammatory myopathies. J Neurol Neurosurg Psychiatry 2004, 75:136-139.
24. Civatte M, Schleinitz N, Krammer P, et al.: Class I MHC detection as a diagnostic tool in noninformative muscle biopsies of patients suffering from dermatomyositis (DM). Neuropathol Appl Neurobiol 2003, 29:546-552.
25. Confalonieri P, Oliva L, Andreetta F, et al.: Muscle inflammation and MHC class I up-regulation in muscular dystrophy with lack of dysferlin: an immunopathological study. J Neuroimmunol 2003, 142:130-136. This is an interesting pathologic study comparing biopsy findings in dysferlinopathy with those seen in PM.
26. Nagaraju K, Raben N, Loeffler L, et al.: Conditional up-regulation of MHC class I in skeletal muscle leads to self-sustaining autoimmune myositis and myositis-specific autoantibodies. Proc Natl Acad Sci U S A 2000, 97:9209-9214.
27. Bushby KM: Diagnostic criteria for the limb-girdle muscular dystrophies: report of the ENMC Consortium on limb-girdle dystrophies. Neuromuscul Disord 1995, 5:71-74.
28. Kirschner J, Bonnemann CG: The congenital and limb-girdle muscular dystrophies: sharpening the focus, blurring the boundaries. Arch Neurol 2004, 61:189-199. This is a good general summary of the clinical and molecular aspects of congenital muscular dystrophies and LGMD.
29. Zatz M, de Paula F, Starling A, et al.: The 10 autosomal recessive limb-girdle muscular dystrophies. Neuromuscul Disord 2003, 13:532-544. This is a detailed review of the clinical and molecular aspects of the recessive LGMDs.
30. Hoffman EP, Rao D, Pachman LM: Clarifying the boundaries between the inflammatory and dystrophic myopathies: insights from molecular diagnostics and microarrays. Rheum Dis Clin North Am 2002, 28:743-757.
31. Stubgen JP: Limb girdle muscular dystrophy: a radiologic and manometric study of the pharynx and esophagus. Dysphagia 1996, 11:25-29.
32. Bansal D, Miyake K, Vogel SS, et al.: Defective membrane repair in dysferlin-deficient muscular dystrophy. Nature 2003, 423:168-172. This excellent study sheds light on the biologic role of dysferlin in calcium-dependent membrane fusion and repair.
33. Davis DB, Doherty KR, Delmonte AJ, et al.: Calcium-sensitive phospholipid binding properties of normal and mutant ferlin C2 domains. J Biol Chem 2002, 277:22883-22888.
34. Ueyama H, Kumamoto T, Horinouchi H, et al.: Clinical heterogeneity in dysferlinopathy. Intern Med 2002, 41:532-536.
35. Illarioshkin SN, Ivanova-Smolenskaya IA, Greenberg CR, et al.: Identical dysferlin mutation in limb-girdle muscular dystrophy type 2B and distal myopathy. Neurology 2000, 55:1931-1933.
36. McNally EM, Ly CT, Rosenmann H, et al.: Splicing mutation in dysferlin produces limb-girdle muscular dystrophy with inflammation. Am J Med Genet 2000, 91:305-312.
37. Rowin J, Meriggioli MN, Cochran EJ, et al.: Prominent inflammatory changes on muscle biopsy in patients with Miyoshi myopathy. Neuromuscul Disord 1999, 9:417-420.
38. Rosenberg NL, Ringel SP, Kotzin BL: Experimental autoimmune myositis in SJL/J mice. Clin Exp Immunol 1987, 68:117-129.
39. Bittner RE, Anderson LV, Burkhardt E, et al.: Dysferlin deletion in SJL mice (SJL-Dysf) defines a natural model for limb girdle muscular dystrophy 2B. Nat Genet 1999, 23:141-142.
40. Muntoni F, Torelli S, Ferlini A: Dystrophin and mutations: one gene, several proteins, multiple phenotypes. Lancet Neurol 2003, 2:731-740. This is an excellent review of the molecular genetics and associated phenotypes of the dystrophinopathies.
41. Escolar DM, Scacheri CG: Pharmacologic and genetic therapy for childhood muscular dystrophies. Curr Neurol Neurosci Rep 2001, 1:168-174.
42. Pegoraro E, Schimke RN, Garcia C, et al.: Genetic and biochemical normalization in female carriers of Duchenne muscular dystrophy: evidence for failure of dystrophin production in dystrophin-competent myonuclei. Neurology 1995, 45:677-690.
43. Hoogerwaard EM, Bakker E, Ippel PF, et al.: Signs and symptoms of Duchenne muscular dystrophy and Becker muscular dystrophy among carriers in The Netherlands: a cohort study. Lancet 1999, 353:2116-2119.
44. Tupler R, Gabellini D: Molecular basis of facioscapulohumeral muscular dystrophy. Cell Mol Life Sci 2004, 61:557-566.
45. Kazemi-Esfarjani P, Skomorowska E, Jensen TD, et al.: A nonischemic forearm exercise test for McArdle disease. Ann Neurol 2002, 52:153-159.
46. Argov Z, Barash V, Soffer D, et al.: Late-onset muscular weakness in phosphofructokinase deficiency due to exon 5/iniron 5 junction poini mutation: a unique disorder or the natural course of this glycolytic disorder? Neurology 1994, 44:1097-1100.
47. Sivakumar K, Vasconcelos O, Goldfarb L, et al.: Late-onset muscle weakness in partial phosphofructokinase deficiency: a unique myopathy with vacuoles, abnormal mitochondria, and absence of the common exon 5/intron 5 junction point mutation. Neurology 1996, 46:1337-1342.
48. Ausems MG, Lochman P, van Diggelen OP, et al.: A diagnostic protocol for adult-onset glycogen storage disease type II. Neurology 1999, 52:851-853.
49. Moufarrej NA, Bertorini TE: Respiratory insufficiency in adult-type acid maltase deficiency. South Med J 1993, 86:560-567.
50. Bornemann A, Besser R, Shin YS, et al.: A mild adult myopathic variant of type IV glycogenosis. Neuromuscul Disord 1996, 6:95-99.
51. Karmaniolas K, Ioannidis P, Liatis S, et al.: Primary carnitine deficiency in a male adult. J Med 2002, 33:105-110.
52. McFarland R, Taylor RW, Turnbull DM: The neurology of mitochondrial DNA disease. Lancet Neurol 2002, 1:343-351.
53. Taylor RW, Schaefer AM, Barron MJ, et al.: The diagnosis of mitochondrial muscle disease. Neuromuscul Disord 2004, 14:237-245. This review provides a useful diagnostic approach to mitochondrial myopathy.
54. Alshekhlee A, Kaminski HJ, Ruff RL: Neuromuscular manifestations of endocrine disorders. Neurol Clin 2002, 20:35-58, v-vi
55. Madariaga MG: Polymyositis-like syndrome in hypothyroidism: review of cases reported over the past twenty-five years. Thyroid 2002, 12:331-336.
56. Nishino I, Noguchi S, Murayama K, et al.: Distal myopathy with rimmed vacuoles is allelic to hereditary inclusion body myopathy. Neurology 2002, 59:1689-1693.
57. Yabe I, Higashi T, Kikuchi S, et al.: GNE mutations causing distal myopathy with rimmed vacuoles with inflammation. Neurology 2003, 61:384-386. This case report demonstrates that patients with hereditary IBM may have inflammation on biopsy.
58. Fidzianska A, Rowinska-Marcinska K, Hausmanowa-Petrusewicz I: Coexistence of X-linked recessive Emery-Dreifuss muscular dystrophy with inclusion body myositis-like morphology. Acta Neuropathol (Berl) 2004, 107:197-203.